BOUT
Innovator IBD Breakout Opportunities ETF
The innovator IBD Breakout Opportunities ETF tracks an index of US-listed stocks that are likely to breakout, as determined by technical analysis. Holdings are weighted by a mix of fundamental and technical factors. The fund may hold 50% T-bills based on technical market signals.
US
EQUITY
Rules-Based
MANAGEMENT STYLE
$ 14.5 M
ASSETS UNDER MGMT
80 bp
EXPENSES
Fund Basics
| Inception date | Sep 12, 2018 |
| Regulation | Open-Ended Fund |
| Fund Website | link... |
| Distributions | Annually |
| Currency | USD |
| Holdings Transparency | Full |
| Derivatives-based | No |
| Options available | No |
| Currency hedged | No |
| Fund of funds | No |
Top 10 Holdings
Complete list +
| HASBRO INC | 8.1 % |
| CAREDX, INC. | 7.4 % |
| PETROLEO BRASILEIRO S.A.-ADR | 6.9 % |
| COCA-COLA BOTTLING CO CONSOL | 6.6 % |
| CHEFS' WAREHOUSE INC/THE | 6.4 % |
| APA CORP. | 6.2 % |
| FIGS, INC. CLASS A | 6.2 % |
| XP INC. CLASS A | 6.1 % |
| DORIAN LPG LTD | 5.9 % |
| HF SINCLAIR CORPORATION | 5.7 % |
Constituent Breakdown
| Number of holdings | 24 |
| Herfindahl-Hirschman Index | 539 |
| Wgt avg mkt cap (mns) | $20,726 |
| Large cap (>$10bn) | 54.4% |
| Mid cap ($2-10bn) | 42.0% |
| Small cap (<$2bn) | 3.0% |
| Developed mkts. | 86.4% |
| Emerging mkts. | 13.0% |
Sector Breakdown
Country Exposure
 |
UNITED STATES | 79.3 % |
 |
BRAZIL | 13.0 % |
 |
BERMUDA | 4.0 % |
 |
GREECE | 2.0 % |
 |
AUSTRALIA | 1.1 % |
Historical Performance
Standardized Performance (as of 09/30/2026)
| YTD | 1 YR | 2 YR | 3 YR | 5 YR | 10 YR | 20 YR | Incep. | |
|---|---|---|---|---|---|---|---|---|
| Price Returns | 17.4% | 9.4% | 7.9% | 12.0% | 4.5% | -- | -- | 6.9% |
| Dividend Yield | 0.0% | 0.0% | 0.3% | 0.7% | 0.7% | -- | -- | 0.5% |
| Total Returns | 17.4% | 9.4% | 8.2% | 12.7% | 5.1% | -- | -- | 7.4% | Ann. Volatility | 22.6% | 22.8% | 21.1% | 19.7% | 19.7% | -- | -- | 22.9% |
Market Correlations
| versus... | Beta | R-squared |
| S&P 500 | 1.29 | 54% |
| MSCI EAFE | 0.95 | 44% |
| MSCI Emg Mkts | 0.61 | 46% |
Liquidity Measures
| Avg. volume (000) | 2 |
| ADV traded (mns) | $0 |
| Turnover | 0.6% |
| Avg. Bid/Ask (% of price) | 0.56% |
Technical Indicators
| 30d moving avg. (EMA) | $42.76 |
| Relative strength (RSI) | 45 |
| MACD/Signal | -0.43/-0.51 |
| Bollinger Bands (Upper/Lower) | $43.81/$41.03 |
| Short interest (% of AUM) | 0.1% |
Distributions
Top Ten Comparable ETFs only shown here. For an extended list become an Individual or Professional subscriber. Start your FREE trial
Comparable ETFs Based on Overlap
| Ticker | Fund Name | Overlap vs. BOUT |
Expenses vs. BOUT |
ALTAR Score™ vs. BOUT |
|---|---|---|---|---|
| FFTY | Innovator IBD 50 ETF | 41.2% | +23 bp | +1.2% |
| FMTM | MarketDesk Focused U.S. Momentum ETF | 15.5% | -35 bp | +3.6% |
| DVLU | First Trust Dorsey Wright Momentum & Value ETF | 12.8% | -20 bp | +6.8% |
| DDIV | First Trust Dorsey Wright Momentum & Dividend ETF | 12.6% | -20 bp | +5.8% |
| FXN | First Trust Energy AlphaDEX Fund | 11.7% | -17 bp | +9.6% |
| QVAL | Alpha Architect US Quantitative Value ETF | 11.1% | -52 bp | +9.7% |
| ABLD | Abacus FCF Real Assets Leaders ETF | 10.6% | -21 bp | +9.3% |
| XOP | State Street SPDR S&P Oil & Gas Exploration & Production ETF | 10.5% | -45 bp | +11.4% |
Risk and Returns: BOUT vs. Comps (1 YR)
Notes: Top 10 overlapping ETFs. Funds with insufficient history not shown. Some funds may overlap. Hover over data point for ticker symbol.
Content on this tab for Individual & Professional subscribers only. Start your FREE trial
Results & Estimates (USD)
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | ||
|---|---|---|---|---|---|---|---|---|---|
| Sales per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Earnings per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Dividends per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Book value per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- |
Return on Equity
Net Margins
Content on this tab for Individual & Professional subscribers only. Start your FREE trial
Valuation Metrics
| Fwd Est | 2025 | 2026 | 2027 | |
| Price-to-sales | --x | --x | --x | --x |
| Price-to-earnings | --x | --x | --x | --x |
| Price-to-cash flow | --x | --x | --x | --x |
| Price-to-growth | --x | --x | --x | --x |
| Price-to-book value | --x | --x | --x | --x |
| Yield | --% | --% | --x | --% |
Based on closing prices from 10/27/2026
Peer Group Comparison
Sample data. Subscribe for access.
Historical Valuation Trends Sample data. Subscribe for access.
Notes: Based on adjusted historical results for current fund constituents. May differ from results achieved by past fund constituents. Max P/E of 100x.
Some content on this tab for Individual & Professional subscribers only. Start your FREE trial
ETF Research Center Rating
0.9%
ALTAR SCORE™
2nd
PERCENTILE
AVOID
ETFRC RATING
There are 1,391 funds in the US Equity category with an average
ALTAR Score™ of 5.5% and a standard deviation
of 2.1%. BOUT's ALTAR Score™ is approximately -2.2 standard
deviations above the category average. This places BOUT in the 2nd percentile
among funds in the category.
Sell-Side Consensus
$49.36
PRICE TARGET
+19.1%
UPSIDE